Evidence map›Paper›PMID 35068798›Full record

ArticleJournal of clinical and experimental hepatology

Diagnosis and Management of Cirrhotic Cardiomyopathy.

Harpreet Kaur, Madhumita Premkumar

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04111133 naunknown statusnot on this map

Efficacy of Carvedilol + Ivabradine vs Carvedilol Alone for Left Ventricular Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality; a Prospective Randomized Controlled Trial.

TypeinterventionalSponsorPost Graduate Institute of Medical Education and Research, ChandigarhRan2020 to 2024Enrolled130ConditionsCirrhotic Cardiomyopathy, Left Ventricular Dysfunction, Cirrhosis, Liver, Portal HypertensionArmsBetablocker + ivabradine, Betablocker
NCT06095466 recruitingnot on this map

Diagnosis and Pathogenetic Mechanisms in Cirrhotic Cardiomyopathy Based on Point-of-care Echocardiography, Biomarkers and Histology

TypeobservationalSponsorPost Graduate Institute of Medical Education and Research, ChandigarhRan2023 to 2026Enrolled150ConditionsCirrhotic Cardiomyopathy, Cirrhosis, Liver, Cardiac DiseaseArmsEchocardiographic assessment, Histopathology and Immunohistochemistry
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Refractory Ascites and the Alfapump.Gastro hep advances · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Harpreet KaurDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, 60012, Chandigarh, India.
Madhumita PremkumarDepartment of Hepatology, Postgraduate Institute of Medical Education and Research, 60012, Chandigarh, India.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCirrhotic cardiomyopathy refers to the structural and functional changes in the heart leading to either impaired systolic, diastolic, electrocardiographic, and neurohormonal changes associated with cirrhosis and portal hypertension. Cirrhotic cardiomyopathy is present in 50% of patients with cirrhosis and is clinically seen as impaired contractility, diastolic dysfunction, hyperdynamic circulation, and electromechanical desynchrony such as QT prolongation. In this review, we will discuss the cardiac physiology principles underlying cirrhotic cardiomyopathy, imaging techniques such as cardiac magnetic resonance imaging and scintigraphy, cardiac biomarkers, and newer echocardiographic techniques such as tissue Doppler imaging and speckle tracking, and emerging treatments to improve outcomes.

methodsWe reviewed available literature from MEDLINE for randomized controlled trials, cohort studies, cross-sectional studies, and real-world outcomes using the search terms "cirrhotic cardiomyopathy," "left ventricular diastolic dysfunction," "heart failure in cirrhosis," "liver transplantation," and "coronary artery disease".

resultsCirrhotic cardiomyopathy is associated with increased risk of complications such as hepatorenal syndrome, refractory ascites, impaired response to stressors including sepsis, bleeding or transplantation, poor health-related quality of life and increased morbidity and mortality. The evaluation of cirrhotic cardiomyopathy should also guide the feasibility of procedures such as transjugular intrahepatic portosystemic shunt, dose titration protocol of betablockers, and liver transplantation. The use of targeted heart rate reduction is of interest to improve cardiac filling and improve the cardiac output using repurposed heart failure drugs such as ivabradine. Liver transplantation may also reverse the cirrhotic cardiomyopathy; however, careful cardiac evaluation is necessary to rule out coronary artery disease and improve cardiac outcomes in the perioperative period.

conclusionMore data are needed on the new diagnostic criteria, molecular and biochemical changes, and repurposed drugs in cirrhotic cardiomyopathy. The use of advanced imaging techniques should be incorporated in clinical practice.

Indexed as

2-AG, 2-arachidonylglycerol2D, two-dimensionalAEA, AnandamideANP, Atrial Natriuretic PeptideASE, the American Society of EchocardiographyAUC, area under the curveBA, bile acidbeta blockerBNP, Brain natriuretic peptideCAD, coronary artery diseaseCB-1, cannabinoid −1CCM, Cirrhotic Cardiomyopathycirrhotic cardiomyopathyCMR, cardiovascular magnetic resonance imagingCO, cardiac outputCT, computed tomographyCTP, Child–Turcotte–PughCVP, central venous pressureDT, deceleration TimeECG, electrocardiogramECV, extracellular volumeEF, Ejection fractionEMD, electromechanical desynchronyESLD, end-stage liver diseaseFXR, Farnesoid X receptorGI, gastrointestinalGLS, Global Longitudinal strainHCN, Hyperpolarization-activated cyclic nucleotide–gatedHE, hepatic encephalopathyhemodynamics in cirrhosisHF, heart failureHfmrEF, heart failure with mid-range ejection fractionHfrEF, heart failure with reduced ejection fractionHO, Heme oxygenaseHPS, hepatopulmonary syndromeHR, heart rateHRS, hepatorenal syndromeHVPG, hepatic venous pressure gradientIVCD, IVC DiameterIVC, Inferior Vena CavaIVS, intravascular volume statusLA, left atriumLAVI, LA volume indexleft ventricular diastolic dysfunctionLGE, late gadolinium enhancementL-NAME, NG-nitro-L-arginine methyl esterLT, liver transplantLVDD, left ventricular diastolic dysfunctionLVEDP, left ventricular end-diastolic pressureLVEDV, LV end diastolic volumeLVEF, left ventricular ejection fractionLVESV, LV end systolic volumeLV, left ventricleLVOT, left ventricular outflow tractMAP, mean arterial pressureMELD, Model for End-Stage Liver DiseaseMRI, Magnetic resonance imagingMR, mitral regurgitationMV, mitral valveNAFLD, Nonalcoholic fatty liver diseaseNO, nitric oxideNOS, Nitric oxide synthasesNTProBNP, N-terminal proBNPPAP, pulmonary artery pressurePCWP, pulmonary capillary wedged pressurePHT, portal hypertensionPWD, Pulsed-wave DopplerRVOT, right ventricular outflow tractRV, right ventricleSA, sinoatrialSD, standard deviationSVR, Systemic vascular resistanceSV, stroke volumeTDI, tissue Doppler imagingTIPS, transjugular intrahepatic portosystemic shuntTRPV1, transient receptor potential cation channel subfamily V member 1TR, Tricuspid valveTTE, transthoracic echocardiographyUSG, ultrasonographyVTI, velocity time integral

Identifiers

PMID35068798
PMCPMC8766707
OpenAlexW3193625614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.